Repurposing old drugs to chemoprevention: The case of metformin

Seminars in Oncology

Volumn 43, Issue 1, 2016, Pages 123-133

  Heckman Stoddard, Brandy M ^a   Gandini, Sara ^b   Puntoni, Matteo ^c   Dunn, Barbara K ^a   Decensi, Andrea ^b,c   Szabo, Eva ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c GALLIERA HOSPITAL   (Italy)

Author keywords

Chemoprevention; Metformin; Repurposing

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ANTINEOPLASTIC ACTIVITY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CARCINOGENESIS; DRUG EFFICACY; DRUG MECHANISM; DRUG REPOSITIONING; DRUG SAFETY; EPIDEMIOLOGICAL DATA; HUMAN; META ANALYSIS (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; ANIMAL; CHEMOPROPHYLAXIS; DIABETES MELLITUS; DRUG EFFECTS; INCIDENCE; METABOLISM; NEOPLASMS; SIGNAL TRANSDUCTION;

ANIMALS; ANTICARCINOGENIC AGENTS; CHEMOPREVENTION; DIABETES MELLITUS; DRUG REPOSITIONING; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; METFORMIN; NEOPLASMS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84960389367     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2015.09.009     Document Type: Review

References (78)

1. E. Giovannucci, D.M. Harlan, M.C. Archer, and et al. Diabetes and cancer: a consensus report Diabetes Care 33 2010 1674 1685
2. E.J. Gallagher, and D. LeRoith Diabetes, antihyperglycemic medications and cancer risk: smoke or fire? Curr Opin Endocrinol Diabetes Obes 20 2013 485 494
3. W.C. Knowler, E. Barrett-Connor, S.E. Fowler, and et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 2002 393 403
4. S. Suissa, and L. Azoulay Metformin and the risk of cancer: time-related biases in observational studies Diabetes Care 35 2012 2665 2673
5. S. Gandini, M. Puntoni, B.M. Heckman-Stoddard, and et al. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders Cancer Prev Res (Phila) 7 2014 867 885
6. A.M. Gonzalez-Angulo, and F. Meric-Bernstam Metformin: a therapeutic opportunity in breast cancer Clin Cancer Res 16 2010 1695 1700
7. M. Pollak Metformin and other biguanides in oncology: advancing the research agenda Cancer Prev Res (Phila) 3 2010 1060 1065
8. M.N. Pollak Investigating metformin for cancer prevention and treatment: the end of the beginning Cancer Discov 2 2012 778 790
9. M. Pollak Potential applications for biguanides in oncology J Clin Invest 123 2013 3693 3700
10. N. Hay, and N. Sonenberg Upstream and downstream of mTOR Genes Dev 18 2004 1926 1945
11. D.G. Hardie Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status Endocrinology 144 2003 5179 5183
12. R.J. Shaw, K.A. Lamia, D. Vasquez, and et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin Science 310 2005 1642 1646
13. S.A. Hawley, A.E. Gadalla, G.S. Olsen, and D.G. Hardie The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism Diabetes 51 2002 2420 2425
14. D.B. Shackelford, and R.J. Shaw The LKB1-AMPK pathway: metabolism and growth control in tumour suppression Nat Rev Cancer 9 2009 563 575
15. D.G. Hardie Neither LKB1 nor AMPK are the direct targets of metformin Gastroenterology 131 2006 973
16. D.M. Gwinn, D.B. Shackelford, D.F. Egan, and et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint Mol Cell 30 2008 214 226
17. J.A. Engelman, and L.C. Cantley Chemoprevention meets glucose control Cancer Prev Res (Phila) 3 2010 1049 1052
18. A. Kalender, A. Selvaraj, S.Y. Kim, and et al. Metformin, independent of AMPK, inhibits mTORC1 in a Rag GTPase-dependent manner Cell Metab 11 2010 390 401
19. Z. Zhu, W. Jiang, M.D. Thompson, J.N. McGinley, and H.J. Thompson Metformin as an energy restriction mimetic agent for breast cancer prevention J Carcinog 10 2011 17
20. M.R. Owen, E. Doran, and A.P. Halestrap Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain Biochem J 348 Pt 3 2000 607 614
21. C. Algire, O. Moiseeva, X. Deschenes-Simard, and et al. Metformin reduces endogenous reactive oxygen species and associated DNA damage Cancer Prev Res (Phila) 5 2012 536 543
22. L. Chen, Y. Shu, X. Liang, and et al. OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin Proc Natl Acad Sci U S A 111 2014 9983 9988
23. R.M. Memmott, J.R. Mercado, C.R. Maier, S. Kawabata, S.D. Fox, and P.A. Dennis Metformin prevents tobacco carcinogen - induced lung tumorigenesis Cancer Prev Res (Phila) 3 2010 1066 1076
24. H.A. Hirsch, D. Iliopoulos, and K. Struhl Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth Proc Natl Acad Sci U S A 110 2013 972 977
25. I. Ben Sahra, K. Laurent, A. Loubat, and et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level Oncogene 27 2008 3576 3586
26. E.A. Queiroz, S. Puukila, R. Eichler, and et al. Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells PLoS One 9 2014 e98207
27. B. Bao, Z. Wang, S. Ali, and et al. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells Cancer Prev Res (Phila) 5 2012 355 364
28. W. Yue, C.S. Yang, R.S. DiPaola, and X.L. Tan Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment Cancer Prev Res (Phila) 7 2014 388 397
29. M. Prlic, and M.J. Bevan Immunology: a metabolic switch to memory Nature 460 2009 41 42
30. N.U. Samarajeewa, S. Ham, F. Yang, E.R. Simpson, and K.A. Brown Promoter-specific effects of metformin on aromatase transcript expression Steroids 76 2011 768 771
31. V.N. Anisimov, L.M. Berstein, P.A. Egormin, and et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice Exp Gerontol 40 2005 685 693
32. V.N. Anisimov, L.M. Berstein, P.A. Egormin, and et al. Metformin slows down aging and extends life span of female SHR mice Cell Cycle 7 2008 2769 2773
33. V.N. Anisimov, L.M. Berstein, I.G. Popovich, and et al. If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice Aging (Albany NY) 3 2011 148 157
34. V.N. Anisimov, T.S. Piskunova, I.G. Popovich, and et al. Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv mice Aging (Albany NY) 2 2010 945 958
35. B. Bojkova, P. Orendas, M. Garajova, and et al. Metformin in chemically-induced mammary carcinogenesis in rats Neoplasma 56 2009 269 274
36. M.D. Thompson, C.J. Grubbs, A.M. Bode, and et al. Lack of effect of metformin on mammary carcinogenesis in nondiabetic rat and mouse models Cancer Prev Res (Phila) 8 2015 231 239
37. K. Hosono, H. Endo, H. Takahashi, and et al. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase Mol Carcinog 49 2010 662 671
38. A. Tomimoto, H. Endo, M. Sugiyama, and et al. Metformin suppresses intestinal polyp growth in ApcMin/+ mice Cancer Sci 99 2008 36 41
39. T. Akinyeke, S. Matsumura, X. Wang, and et al. Metformin targets c-MYC oncogene to prevent prostate cancer Carcinogenesis 34 2013 2823 2832
40. K. Bhalla, B.J. Hwang, R.E. Dewi, and et al. Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis Cancer Prev Res (Phila) 5 2012 544 552
41. L.A. Checkley, O. Rho, J.M. Angel, and et al. Metformin inhibits skin tumor promotion in overweight and obese mice Cancer Prev Res (Phila) 7 2014 54 64
42. M.B. Schneider, H. Matsuzaki, J. Haorah, and et al. Prevention of pancreatic cancer induction in hamsters by metformin Gastroenterology 120 2001 1263 1270
43. K. Tajima, A. Nakamura, J. Shirakawa, and et al. Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice Am J Physiol Endocrinol Metab 305 2013 E987 E998
44. L. Vitale-Cross, A.A. Molinolo, D. Martin, and et al. Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions Cancer Prev Res (Phila) 5 2012 562 573
45. A. Decensi, M. Puntoni, P. Goodwin, and et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis Cancer Prev Res (Phila) 3 2010 1451 1461
46. M. Franciosi, G. Lucisano, E. Lapice, G.F. Strippoli, F. Pellegrini, and A. Nicolucci Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review PLoS One 8 2013 e71583
47. H. Noto, A. Goto, T. Tsujimoto, and M. Noda Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis PLoS One 7 2012 e33411
48. D. Soranna, L. Scotti, A. Zambon, and et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis Oncologist 17 2012 813 822
49. B. Thakkar, K.N. Aronis, M.T. Vamvini, K. Shields, and C.S. Mantzoros Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies Metabolism 62 2013 922 934
50. L. Wu, J. Zhu, L.J. Prokop, and M. Hassan Murad Pharmacologic therapy of diabetes and overall cancer risk and mortality: a meta-analysis of 265 studies Sci Rep 5 2015 10147
51. B. Bonanni, M. Puntoni, M. Cazzaniga, and et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial J Clin Oncol 30 2012 2593 2600
52. X. He, F.J. Esteva, J. Ensor, G.N. Hortobagyi, M.H. Lee, and S.C. Yeung Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer Ann Oncol 23 2012 1771 1780
53. B.X. Tan, W.X. Yao, J. Ge, and et al. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes Cancer 117 2011 5103 5111
54. H.A. Hirsch, D. Iliopoulos, P.N. Tsichlis, and K. Struhl Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission Cancer Res 69 2009 7507 7511
55. P.J. Goodwin, K.I. Pritchard, M. Ennis, M. Clemons, M. Graham, and I.G. Fantus Insulin-lowering effects of metformin in women with early breast cancer Clin Breast Cancer 8 2008 501 505
56. P.J. Goodwin, M. Ennis, K.I. Pritchard, and et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study J Clin Oncol 20 2002 42 51
57. C. Campagnoli, P. Pasanisi, C. Abba, and et al. Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study Clin Breast Cancer 12 2012 175 182
58. S. Hadad, T. Iwamoto, L. Jordan, and et al. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial Breast Cancer Res Treat 128 2011 783 794
59. S. Niraula, R.O. Dowling, M. Ennis, and et al. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study Breast Cancer Res Treat 135 2012 821 830
60. K. Kalinsky, K.D. Crew, S. Refice, and et al. Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer Cancer Invest 32 2014 150 157
61. K.M. Schuler, B.S. Rambally, M.J. DiFurio, and et al. Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer Cancer Med 4 2015 161 173
62. A. Mitsuhashi, T. Kiyokawa, Y. Sato, and M. Shozu Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial Cancer 120 2014 2986 2995
63. A. Chak, N.S. Buttar, N.R. Foster, and et al. Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's esophagus Clin Gastroenterol Hepatol 13 2015 665 672 e664
64. K. Hosono, H. Endo, H. Takahashi, and et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial Cancer Prev Res (Phila) 3 2010 1077 1083
65. A.M. Joshua, V.E. Zannella, M.R. Downes, and et al. A pilot /'window of opportunity/' neoadjuvant study of metformin in localised prostate cancer Prostate Cancer Prostatic Dis. 17 2014 252 258
66. Monash University. The effects of metformin on the LKB1/AMP-activated protein kinase (AMPK) pathway in breast tissue, a randomized clinical trial. Available at: http://apps.who.int/trialsearch/trial.aspx?trialid = ACTRN12610000219088. Accessed June 30, 2012
67. Columbia University. Metformin pre-surgical pilot study. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00930579. Accessed June 30, 2012
68. Instituto Nacional de Cancer Brazil. The use of metformin in early breast cancer patients pre-surgery. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01302002. Accessed June 30, 2012
69. Vanderbilt-Ingram Cancer Center. Metformin hydrochloride in treating women with stage i or stage ii breast cancer that can be removed by surgery. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00984490. Accessed June 30, 2012
70. Oxford University Hospitals NHS Trust. Effect of metformin on breast cancer metabolism. Available at: http://clinicaltrials.gov/ct2/show/NCT01266486. Accessed June 30, 2012
71. NCIC Clinical Trials Group. A phase III randomized trial of metformin vs placebo in early stage breast cancer. Available at: http://clinicaltrials.gov/ct2/show/study/NCT01101438. Accessed June 30, 2012
72. Seoul National University Hospita. Efficacy and safety of adjuvant metformin for operable breast cancer patients. Available at: http://clinicaltrials.gov/ct2/show/NCT00909506. Accessed June 30, 2012
73. University of California- San Diego. Reach for Health Study: obesity-related mechanisms and mortality in breast cancer survivors. Available at: http://clinicaltrials.gov/ct2/show/NCT01302379. Accessed June 30, 2012
74. University of California- Irvine. A trial of metformin for colorectal cancer risk reduction among patients with a history of colorectal adenomas and elevated body mass index. Available at: http://clinicaltrials.gov/ct2/show/NCT01312467. Accessed June 30, 2012
75. University of Arkansas. Effect of metformin on biomarkers of colorectal tumor cell growth. Available at: http://clinicaltrials.gov/ct2/show/NCT01632020. Accessed June 30, 2012
76. Dana-Farber Cancer Institute. Exercise and metformin in colorectal cancer survivors. Available at: http://clinicaltrials.gov/ct2/show/NCT01340300. Accessed June 30, 2012
77. Chiba University. A pilot study of the medroxyprogesterone + metformin combination therapy for the endometrial cancer. Available at: http://apps.who.int/trialsearch/trial.aspx?trialid = JPRN-UMIN000002210. Accessed June 30, 2012
78. National Cancer Institute (NCI). Metformin hydrochloride in treating patients with prostate cancer undergoing surgery. Available at: http://clinicaltrials.gov/ct2/show/NCT01433913. Accessed June 30, 2012